Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 151 - 200 out of 115,935

Document Document Title
WO/2024/034644A1
The present invention provides a compound for treating or preventing reduced intracellular ATP levels. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and...  
WO/2024/033293A1
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).  
WO/2024/032501A1
Provided are a compound of formula 0, a stereoisomer thereof, a tautomer thereof, a geometric isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a polymorph thereof, a solvate thereof, a hydrate thereof, a...  
WO/2024/033479A1
The application relates to compounds of formula (B1A), (B1B), (B1C) or a salt, a solvate, a hydrate, a polymorph, a tautomer, a racemate or a stereoisomer thereof, to pharmaceutical compositions comprising such a compound, and to the com...  
WO/2024/032530A1
Provided are an aromatic heterocyclic cyclohexyl aminoalkyl piperidine derivative, a preparation method and a use thereof. Specifically, provided are a compound of formula (I), a stereoisomer thereof, a tautomer thereof or a pharmaceutic...  
WO/2024/035194A1
The present invention relates to a novel heteroaryl-substituted derivative and a composition for preventing or treating neurodegenerative diseases, cancer, and inflammatory diseases comprising same. The heteroaryl-substituted derivative ...  
WO/2024/036226A1
Provided herein is a method for treating autism or autism spectrum disorders. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). Also provided is a composition for treating autis...  
WO/2024/035268A2
Pharmaceutical compositions and methods for treating tauopathies are provided.  
WO/2024/033539A1
The present disclosure provides cannabinoid drug substances, pharmaceutical compositions and methods of treating neurological or neurodegenerative disorders in a human patient.  
WO/2024/033895A2
The present disclosure relates to antisense oligonucleotides, which target IDO1 mRNA in a cell, leading to reduced expression of IDO1 protein. Reduction of IDO1 protein expression is beneficial for the treatment of certain medical disord...  
WO/2024/033459A1
The present invention relates to pharmaceutical compositions comprising 5-ethyl-4- methyl-N-[4-[(2S) morpholin-2-yl]phenyl]-1H-pyrazole-3-carboxamide (ralmitaront), to processes for their preparation and their use in medical treatment.  
WO/2024/031889A1
The present invention relates to the field of biotechnology, and specifically, to use of a gene delivery system in delivering a gene to microglial cells, or in preparing a reagent for delivering a gene to microglial cells. The gene deliv...  
WO/2024/032390A1
Provided are a macrocyclic triazole compound represented by formula I or an isotope labeled compound thereof, or an optical isomer, a geometric isomer, a tautomer or an isomer mixture thereof, or a pharmaceutically acceptable salt, or a ...  
WO/2024/032507A1
Provided are a metal-phospholipid complex, a metal-phospholipid complex particle, a drug-lipid particle, a method for preparing same, and use thereof, which relate to the field of biotechnology. The metal-phospholipid complex is formed b...  
WO/2024/034424A1
[Problem] The purpose of the present invention is to provide a novel composition for enhancing motivation and/or a composition for improving wakefulness upon getting out of bed. [Solution] The aforementioned problem is solved by a compos...  
WO/2024/035613A1
Provided herein are compositions and methods for treating and/or ameliorating the FOXG1 syndrome or the symptoms associated therewith. The compositions and methods disclosed herein utilize antisense oligonucleotides that target long non-...  
WO/2024/030332A1
The present disclosure relates to methods for treating a neurological disorder, such as Parkinson's Disease (PD), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), and Alzheimer's Disease. The methods include adm...  
WO/2024/029755A1
The present invention relates to an animal model of Charcot-Marie-Tooth disease caused by K141N or K141T mutations in HSPB8. In this animal model expressing the K141N or K141T mutant HSPB8 protein, symptoms of Charcot-Marie-Tooth disease...  
WO/2024/029239A1
The purpose of the present invention is to provide a novel affective disorder ameliorating agent. A PKCγ activity inhibitor is useful as an active ingredient for an affective disorder ameliorating agent.  
WO/2024/029489A1
Provided herein are compounds and compositions useful in inhibiting a receptor tyrosine kinase, KIT. The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or cond...  
WO/2024/026574A1
The present application relates to 3-cyclic amine-indole dimers of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to t...  
WO/2024/030627A1
Provided herein are compounds having a structure of formula (A), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rd, and n are described herein. Also provided herein are compositions comprising compounds of Formula ...  
WO/2024/029992A1
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, which is known to be a causative agent of Alzheimer's disease, and a composition for the treatment and prevention of Alzheimer's diseas...  
WO/2024/031053A1
Provided herein are TDP-43 variants in which a prion-like domain (PLD) of the TDP-43 variant is mutated to have more aromatic amino acids and/or aromatic amino acids that are more evenly spaced than in a PLD from a wild type TDP-43, nucl...  
WO/2024/029242A1
Disclosed is a linear peptide or cyclic peptide having an amino acid sequence represented by formula (1): XN-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15 (1), or a pharmacologically acceptable salt thereof. Binding this peptide to LRP1 makes i...  
WO/2024/028483A1
The present invention relates to brain derived nerve factor (BDNF) for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said BDNF is administered intranasally to said subject.  
WO/2024/028779A1
Provided herein are vaporizer formulations comprising fungal material from Amanita muscaria and/or an extract thereof, as well as devices comprising the same. Also provided are methods of using the disclosed formulations and devices to m...  
WO/2024/030628A1
The present invention provides deuterium-enriched compounds, compositions thereof, and methods of using the same.  
WO/2024/026573A1
The present application relates to 3-ethylamino-indole dimers of general Formula I, to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treat...  
WO/2024/028349A2
The present invention relates to levodopa for preventing the development of addiction and/or dependence to prescribed stimulants in a subject treated with stimulants. The present invention also relates to the use of a composition, pharma...  
WO/2024/028495A1
The present invention relates generally to substituted ergoline compounds and compositions, more particularly new lysergamide derivatives and compositions, and applications of these. The invention furthermore relates to a new production ...  
WO/2024/028487A1
The present invention relates to nerve growth factor (NGF) or a mutein thereof for use in the prevention or treatment of sensorineural hearing loss in a subject, wherein said NGF is administered intranasally to said subject.  
WO/2024/030504A1
The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of biomarkers in such patients allows identification of those patients who will res...  
WO/2024/026568A1
Disclosed are novel fused heterocyclic mescaline derivative compounds, notably fused heterocyclic mescaline derivatives and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compound...  
WO/2024/028808A1
The present disclosure relates to compounds of Formula (I) which modulate the activity of protein phosphatase 2A (PP2A). The compounds of the present disclosure are useful in treating, preventing, and/or ameliorating cancer, diabetes, au...  
WO/2024/027723A1
Disclosed in the present invention are a crystal form, a salt type and a composition of a pyridazine compound and a preparation method therefor, and specifically disclosed are a method for preparing a crystal form A and a composition of ...  
WO/2024/029638A1
The present invention relates to a series of novel heterocyclyl-phenyl-methylamine derivatives, a preparation method therefor, and a use thereof for prevention, alleviation, or treatment of multiple sclerosis.  
WO/2024/028731A1
Provided are novel multispecific antibodies comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a thir...  
WO/2024/029678A1
The present invention relates to a use of PDH inhibitors in the treatment of neurodegenerative diseases, and according to the present invention, in a DJ-1 deletion Parkinson's disease Drosophila model, by activation of PDK, promotion of ...  
WO/2024/029535A1
The present invention provides a polypeptide that specifically recognizes a structurally abnormal protein caused by misfolding, etc. in mammals, and a detection agent and a reduction agent for a structurally abnormal protein with the use...  
WO/2024/027752A1
Provided are a pharmaceutical composition comprising a heterocyclic compound, a preparation method therefor, and use thereof. Further provided is a pharmaceutical composition Q, comprising a substance X and a pharmaceutical excipient, th...  
WO/2024/027751A1
Disclosed are a crystal form of a heterocyclic compound, a preparation method therefor, and the use thereof. The heterocyclic compound is the compound represented by formula I. For the crystal form thereof, the X-ray powder diffraction p...  
WO/2024/030560A2
Power equipment includes a chassis, an implement coupled to the chassis, and a battery system coupled to the chassis. The battery system includes a first battery pack, a second battery pack, a circuit including a first switch configured ...  
WO/2024/029995A1
The present invention relates to a peptide capable of directly binding to amyloid beta protein Aβ42, known to be a causative agent of Alzheimer's disease, and a composition for treating and preventing Alzheimer's disease, comprising the...  
WO/2024/028516A1
A synthesis method for the preparation of a cannabinoid selected from cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), comprising the steps of: a) dissolving olivetol in dichloromethane (DCM) with stirring; b) adding FeCl3 * 6H2O as...  
WO/2024/028611A1
The present invention provides for an effective pharmacological therapy for obsessive compulsive disorder.  
WO/2024/029962A1
The present invention relates to use of a novel PPAR activity modulator for the prevention, amelioration or treatment of degenerative brain diseases and, more specifically, provides a composition for the prevention, amelioration or treat...  
WO/2024/029630A1
The present disclosure provides a cyclic peptide derivative, a method for producing the same, and a composition. The present disclosure pertains to a compound for neural cell activity regulation. More specifically, the compound of the pr...  
WO/2024/028732A1
Provided are novel multispecific antibodies comprising at least one of a first antigen-binding region and a second antigen-binding region each capable of binding specifically to human epidermal growth factor receptor 2 (HER2), and a thir...  
WO/2024/027800A1
The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical ...  

Matches 151 - 200 out of 115,935